Silo Pharma, Inc. 8-K Filing: Key Updates as of December 20, 2024
Based on the provided section of the financial report, here are the key pieces of information and insights:
- Company Information:
- Name: Silo Pharma, Inc.
- CIK: 0001514183
- State: Nevada (NV)
- Address: 677 N. Washington Boulevard, Sarasota, FL 34236
- Phone: 718-400-9031
- Common Stock Symbol: SILO
- Exchange: NASDAQ
- Filing Details:
- Form Type: 8-K (which is typically used to report major events that shareholders should know about)
- Filing Date: December 20, 2024
- Financial Context:
- Reporting Period: The financial data is as of December 20, 2024.
- Currency: All amounts are reported in U.S. Dollars (USD).
- Par Value of Common Stock: $0.0001 per share.
- Stock Information:
- Unit of Measure: The financial report includes shares and USD per share valuation.
- Additional Notes:
- The document is written in XBRL format, which is a standard for communicating financial data.
- The context indicates that this report contains information relevant to the specified date and may pertain to a significant event or update regarding Silo Pharma, Inc.
Insights:
- As this is an 8-K filing, it suggests that Silo Pharma, Inc. potentially announced a significant development or event on or before December 20, 2024. Investors and stakeholders should review this filing further to understand the implications of the reported event.
- The par value of the common stock is notably low, which may indicate a strategy for maintaining flexibility in financial operations or future equity financing.
- The listing on NASDAQ under the symbol SILO suggests that the company is publicly traded and subject to regulatory disclosures, offering transparency to investors.
This information is essential for investors, analysts, and stakeholders who are evaluating the company's current status and future prospects.